ArticleCase reports in hematology2025

Potential Off-Target Effect of Gilteritinib With Venetoclax Decreases Tumor Burden for Patients With Relapsed/Refractory Wild-Type

Shuting Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.